Attached files
| file | filename |
|---|---|
| EX-10.85 - EXHIBIT 10.85 - IMMUNE PHARMACEUTICALS INC | t1702770_ex10-85.htm |
| EX-10.84 - EXHIBIT 10.84 - IMMUNE PHARMACEUTICALS INC | t1702770_ex10-84.htm |
| EX-5.1 - EXHIBIT 5.1 - IMMUNE PHARMACEUTICALS INC | t1702770_ex5-1.htm |
| EX-3.10 - EXHIBIT 3.10 - IMMUNE PHARMACEUTICALS INC | t1702770_ex3-10.htm |
| EX-1.1 - EXHIBIT 1.1 - IMMUNE PHARMACEUTICALS INC | t1702770_ex1-1.htm |
| S-1/A - AMENDMENT NO. 2 TO FORM S-1 - IMMUNE PHARMACEUTICALS INC | t1702770-s1a.htm |
Exhibit 23.1
Immune Pharmaceuticals, Inc.
550 Sylvan Avenue, Suite 101
Englewood Cliffs, NJ 07632
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated May 17, 2017, relating to the consolidated financial statements of Immune Pharmaceuticals, Inc., which is contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
| /S/ BDO USA, LLP | |
| New York, New York | |
| October 11, 2017 |